Daniel M.F. Claassens

901 total citations · 1 hit paper
16 papers, 517 citations indexed

About

Daniel M.F. Claassens is a scholar working on Cardiology and Cardiovascular Medicine, Surgery and Internal Medicine. According to data from OpenAlex, Daniel M.F. Claassens has authored 16 papers receiving a total of 517 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Cardiology and Cardiovascular Medicine, 11 papers in Surgery and 8 papers in Internal Medicine. Recurrent topics in Daniel M.F. Claassens's work include Antiplatelet Therapy and Cardiovascular Diseases (15 papers), Acute Myocardial Infarction Research (9 papers) and Venous Thromboembolism Diagnosis and Management (8 papers). Daniel M.F. Claassens is often cited by papers focused on Antiplatelet Therapy and Cardiovascular Diseases (15 papers), Acute Myocardial Infarction Research (9 papers) and Venous Thromboembolism Diagnosis and Management (8 papers). Daniel M.F. Claassens collaborates with scholars based in Netherlands, United Kingdom and Saudi Arabia. Daniel M.F. Claassens's co-authors include Jurriën M. ten Berg, Folkert W. Asselbergs, Thomas O. Bergmeijer, Paul W.A. Janssen, Gerrit J.A. Vos, Vera H.M. Deneer, Willem J.M. Dewilde, Arnoud W.J. van ‘t Hof, Jean‐Paul R. Herrman and Emanuele Barbato and has published in prestigious journals such as New England Journal of Medicine, SHILAP Revista de lepidopterología and European Heart Journal.

In The Last Decade

Daniel M.F. Claassens

15 papers receiving 507 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A Genotype-Guided Strategy for Oral P2Y ₁₂ Inhibitors in Primary PCI

2019 378 citations Daniel M.F. Claassens, Gerrit J.A. Vos et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Daniel M.F. Claassens

Since Specialization

Citations

This map shows the geographic impact of Daniel M.F. Claassens's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel M.F. Claassens with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel M.F. Claassens more than expected).

Fields of papers citing papers by Daniel M.F. Claassens

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel M.F. Claassens. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel M.F. Claassens. The network helps show where Daniel M.F. Claassens may publish in the future.

Co-authorship network of co-authors of Daniel M.F. Claassens

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel M.F. Claassens. A scholar is included among the top collaborators of Daniel M.F. Claassens based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel M.F. Claassens. Daniel M.F. Claassens is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

#	Work	Indexed citations
1	Dual antiplatelet therapy de-escalation in acute coronary syndrome: an individual patient meta-analysis 2023 ·European Heart Journal ·Jeehoon Kang, Konstantinos D. Rizas, Kyung Woo Park, (unknown), (unknown), Daniel M.F. Claassens, Eun Ho Choo, Dániel Aradi, Steffen Maßberg, Doyeon Hwang, Jung‐Kyu Han, Han‐Mo Yang, Hyun‐Jae Kang, Kiyuk Chang, J M Ten Berg, Dirk Sibbing, Bon‐Kwon Koo, Hyo‐Soo Kim	27
2	Effects of CYP3A422 and CYP3A5 on clinical outcome in patients treated with ticagrelor for ST-segment elevation myocardial infarction: POPular Genetics sub-study 2022 ·Frontiers in Pharmacology* ·(unknown), Thomas O. Bergmeijer, (unknown), Dean R.P.P. Chan Pin Yin, (unknown), Joyce Peper, Willem L. Bor, Daniel M.F. Claassens, Ron H. N. van Schaik, Jurriën M. ten Berg	2
3	Efficacy and safety of glycoproteinIIb/IIIainhibitors in addition toP2Y₁₂inhibitors inST‐segment elevation myocardial infarction: A subanalysis of thePOPularGenetics trial 2021 ·Catheterization and Cardiovascular Interventions ·(unknown), Daniel M.F. Claassens, Renicus S. Hermanides, Gerrit J.A. Vos, Thomas O. Bergmeijer, Johannes C. Kelder, Vera H.M. Deneer, Arnoud W.J. van ‘t Hof, Jurriën M. ten Berg	4
4	Factor V Leiden and the Risk of Bleeding in Patients With Acute Coronary Syndromes Treated With Antiplatelet Therapy: Pooled Analysis of 3 Randomized Clinical Trials 2021 ·Journal of the American Heart Association ·Bakhtawar K. Mahmoodi, Niclas Eriksson, Stephanie Ross, Daniel M.F. Claassens, Folkert W. Asselbergs, Karina Meijer, Agneta Siegbahn, Stefan James, Guillaume Paré, Lars Wallentin, Jurriën M. ten Berg	2
5	Clopidogrel Versus Ticagrelor or Prasugrel After Primary Percutaneous Coronary Intervention According to CYP2C19 Genotype 2021 ·Circulation Cardiovascular Interventions ·Daniel M.F. Claassens, Thomas O. Bergmeijer, Gerrit J.A. Vos, Renicus S. Hermanides, Arnoud W.J. van ‘t Hof, Pim van der Harst, Emanuele Barbato, Carmine Morisco, (unknown), Folkert W. Asselbergs, Arend Mosterd, Jean‐Paul R. Herrman, Willem J.M. Dewilde, Paul W.A. Janssen, Johannes C. Kelder, Bakhtawar K. Mahmoodi, Vera H.M. Deneer, Jurriën M. ten Berg	17
6	Prevalence of CYP2C192* carriers in Saudi ischemic stroke patients and the suitability of using genotyping to guide antiplatelet therapy in a university hospital setup 2021 ·Drug Metabolism and Personalized Therapy ·Abdullah M. Al‐Rubaish, Fahad Al‐Muhanna, Abdullah Alshehri, Abdulla Alsulaiman, (unknown), (unknown), (unknown), (unknown), Mohammed Akhtar, Cyril Cyrus, Daniel M.F. Claassens, Folkert W. Asselbergs, Amein K. Al‐Ali	6
7	Cost Effectiveness of a CYP2C19 Genotype-Guided Strategy in Patients with Acute Myocardial Infarction: Results from the POPular Genetics Trial 2021 ·American Journal of Cardiovascular Drugs ·Daniel M.F. Claassens, (unknown), Gerrit J.A. Vos, Thomas O. Bergmeijer, Renicus S. Hermanides, Arnoud W.J. van ‘t Hof, Pim van der Harst, Emanuele Barbato, Carmine Morisco, (unknown), Folkert W. Asselbergs, Arend Mosterd, Jean‐Paul R. Herrman, Willem J.M. Dewilde, Maarten J. Postma, Vera H.M. Deneer, Jurriën M. ten Berg, Cornelis Boersma	16
8	Bedside testing of CYP2C19 vs. conventional clopidogrel treatment to guide antiplatelet therapy in ST-segment elevation myocardial infarction patients 2021 ·International Journal of Cardiology ·Abdullah M. Al‐Rubaish, Fahad Al‐Muhanna, Abdullah Alshehri, (unknown), (unknown), (unknown), (unknown), Cyril Cyrus, (unknown), Chittibabu Vatte, Bao‐Li Loza, Daniel M.F. Claassens, Folkert W. Asselbergs, Amein K. Al‐Ali	14
9	Prevalence of CYP2C192* carriers in Saudi ischemic stroke patients and the suitability of using genotyping to guide antiplatelet therapy in a university hospital setup 2021 ·Drug Metabolism and Personalized Therapy ·Abdullah M. Al‐Rubaish, Fahad Al‐Muhanna, Abdullah Alshehri, Abdulla Alsulaiman, (unknown), (unknown), (unknown), (unknown), Mohammed Akhtar, Cyril Cyrus, Daniel M.F. Claassens, Folkert W. Asselbergs, Amein K. Al‐Ali	2
10	Rationale and Design of the Future Optimal Research and Care Evaluation in Patients with Acute Coronary Syndrome (FORCE-ACS) Registry: Towards “Personalized Medicine” in Daily Clinical Practice 2020 ·Journal of Clinical Medicine ·Dean R.P.P. Chan Pin Yin, (unknown), (unknown), (unknown), Melvyn Tjon Joe Gin, (unknown), (unknown), Daniel M.F. Claassens, Marieke E. Gimbel, (unknown), Willem L. Bor, Tom Oirbans, (unknown), Georgios J. Vlachojannis, Rutger J. van Bommel, Yolande Appelman, José P.S. Henriques, Wouter J. Kikkert, Jurriën M. ten Berg	8
11	Bedside testing of CYP2C19 gene for treatment of patients with PCI with antiplatelet therapy 2020 ·BMC Cardiovascular Disorders ·Abdullah M. Al‐Rubaish, Fahad Al‐Muhanna, Abdullah Alshehri, (unknown), (unknown), (unknown), (unknown), Cyril Cyrus, (unknown), Chittibabu Vatte, Daniel M.F. Claassens, Jurriën M. ten Berg, Folkert W. Asselbergs, Amein K. Al‐Ali	6
12	De-Escalation of Antiplatelet Treatment in Patients with Myocardial Infarction Who Underwent Percutaneous Coronary Intervention: A Review of the Current Literature 2020 ·Journal of Clinical Medicine ·Daniel M.F. Claassens, Dirk Sibbing	10
13	A Genotype-Guided Strategy for Oral P2Y ₁₂ Inhibitors in Primary PCI breakdown → 2019 ·New England Journal of Medicine ·Daniel M.F. Claassens, Gerrit J.A. Vos, Thomas O. Bergmeijer, Renicus S. Hermanides, Arnoud W.J. van ‘t Hof, Pim van der Harst, Emanuele Barbato, Carmine Morisco, (unknown), Folkert W. Asselbergs, Arend Mosterd, Jean‐Paul R. Herrman, Willem J.M. Dewilde, Paul W.A. Janssen, Johannes C. Kelder, Maarten J. Postma, Anthonius de Boer, Cornelis Boersma, Vera H.M. Deneer, Jurriën M. ten Berg	378
14	Is there a place for heart-type fatty acid binding protein in the era of high-sensitive cardiac troponin T for the diagnosis of acute myocardial infarction? A systematic review 2019 ·SHILAP Revista de lepidopterología ·Daniel M.F. Claassens, (unknown), Thomas O. Bergmeijer, Dean R.P.P. Chan Pin Yin, Jurriën M. ten Berg	0
15	Feasibility and Implementation of CYP2C19 Genotyping in Patients Using Antiplatelet Therapy 2018 ·Pharmacogenomics ·Thomas O. Bergmeijer, Gerrit J.A. Vos, Daniel M.F. Claassens, Paul W.A. Janssen, (unknown), (unknown), Folkert W. Asselbergs, Jurriën M. ten Berg, Vera H.M. Deneer	20
16	Perioperative management of antiplatelet treatment in patients undergoing isolated coronary artery bypass grafting in Dutch cardiothoracic centres 2017 ·Netherlands Heart Journal ·Paul W.A. Janssen, Daniel M.F. Claassens, Laura M. Willemsen, Thomas O. Bergmeijer, Patrick Klein, Jurriën M. ten Berg	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact